<DOC>
	<DOCNO>NCT00483535</DOCNO>
	<brief_summary>GW273225 development epilepsy bipolar disorder affect woman child bear potential . A clear understanding potential interaction oral contraceptive GW273225 therefore important clinical investigation GW273225 large number patient . This study investigate whether effect GW273225 upon component combine oral contraceptive , also whether take oral contraceptive affect pharmacokinetics ( PK ) GW273225 . 26 healthy female subject , age 18-45 year take oral contraceptive ( 150ug levonorgestrel 30ug ethinylestrdiol ; The study include screen period , two cycle oral contraceptive GW273225 25 mg per day administer start second COC cycle 47 day . There follow-up visit 14-21 day later .</brief_summary>
	<brief_title>Oral Contraceptive Interaction Study GW273225</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy female subject age 18 45 year , inclusive . Body weight &gt; 50 kg Body Mass Index ( BMI ) within range 1929.9 kg/m2 inclusive . Female subject child bear potential eligible participate establish Microgynon 30 Ovranette previous month If take similar ethinyl oestradiol dose ( 30 35 mcg ) combine progestogen fix dose 21 day willing switch Microgynon 30 Subjects use additional contraception describe protocol . One method list protocol acceptable conjunction COC method contraception indisputable data &gt; 99 % effective , otherwise use barrier method ( condom occlusive cap ( diaphragm cervical/vault cap ) use spermicidal foam/gel/film/cream/suppository ) . Subjects must smoke â‰¤ 10 cigarette per day . No abnormality relevant clinical examination . A subject clinical abnormality may include Investigator consultation GSK Medical Monitor consider abnormality introduce additional risk factor interfere study procedure . No abnormality relevant clinical chemistry haematology examination prestudy medical examination . Subjects laboratory parameter outside reference range age group include Investigator consultation GSK Medical Monitor consider finding introduce additional risk factor . A 12lead ECG vital sign prestudy medical examination , normal . ( include QTc &lt; 450msec ) The subject sign dated write informed consent prior admission study The subject able understand comply protocol requirement , instruction protocolstated restriction . History evidence drug alcohol abuse within six month study start . Weekly alcohol intake 14 unit average daily intake great 2 unit . Female subject pregnant ( positive serum human chorionic gonadotrophin ( hCG ) test screen ) lactating . HIV , Chronic hepatitis B C , evidence positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody Subject receive prescribed nonprescribed medication ( include vitamin herbal remedy ) within 14 day prior day 1 opinion investigator , could interfere study procedure compromise safety . History gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . History thrombotic event presence significant risk factor thrombosis . Supine Blood Pressure great equal 140/90 . Progestogen release IUD contraceptive . Participation trial drug within 84 day start study . Donation 1500 mL blood previous 12 month . History presence condition contraindicate combined oral contraceptive . Any subject potential side effect GW273225 could affect professional occupation , e.g . operate machinery , drive . Any subject refrain drive duration administration GW273225 3 day afterwards . History clinically relevant skin rash , opinion investigator , might interfere conduct study . Subject current past history seizure disorder brain injury ( traumatic diseaserelated ) , condition , opinion investigator , predispose seizure ; subject treat medication treatment regimens low seizure threshold ; subject undergoing abrupt discontinuation alcohol sedative ( include benzodiazepine ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Gw273225 , Oral Contraceptive Interaction</keyword>
</DOC>